A 33-year-old male with no known risk factors for hypercoagulability developed a massive thrombi in the inferior vena cava (IVC). The patient had a history of both pulmonary embolism and embolism-related syncope.
Introduction
Pulmonary embolism (PE) is a major complication in patients with deep vein thrombosis (DVT). Management of patients with DVT requires anticoagulation and thrombolysis in select cases.
Percutaneous placement of a permanent inferior vena cava (IVC) filter has also been used to supplement thrombolysis under certain circumstances.
Concerns about possible long-term complications arising in younger patients or in patients with a long permanent filter. Prior to removal, inferior vena cavography was performed, which revealed some thrombi trapped in the temporary filter. However, we determined that the trapped thrombi would not pose a problem during removal of the temporary filter. Before implantation of the permanent filter (Titanium Greenfield filter, Boston Scientific Corporation, Massachusetts, USA), the temporary filter was left in place to prevent the possible migration of the large thrombus.
Venograpy was performed again and no new thrombi were found in the temporary filter. The temporary filter was then removed (Fig. 5) and replaced with the permanent filter suprarenally without complication. Warfarin was administered at a dose of 3.5 to 4.5 mg and the dosage was adjusted to maintain an international normalized ratio (INR) of 1.5 to 2.0. Intravenous L. M.W. heparin was administered for 26 days after implantation of the permanent filter. Laboratory data revealed a gradual increase in FDP-E concentration during the first two weeks, then normalization with levels of D-dimer, TAT and PIC. Two year after discharge, the patient is doing well without any complications from the permanent filter.
Discussion
This is a report of a young male with massive idiopathic DVT complicated by both pulmonary embolism and an episode of embolism-related syncope.
We used a temporary filtering device during invasive thombolytic therapy. Temporary filters have been available in Japan since February 1997. The Antheor filter system is placed via the brachial and femoral or jugular veins using a long catheter.
The double-helix, biocarbon-coated basket, which is made of phynoxalloy, is positioned by the effect of the opening force on extrusion from a catheter prepositioned over a guidewire and can be removed by exerting traction toward the catheter.
The filter is 31 mm in diameter and 50 mm in length. It is a self-centering system, radiopaque and MRI compatible.
The current indications for the placement of a temporary vena cava filter are as follows : 1) during thrombolysis of DVT ; 2) as pre-operative prophylaxis (high risk orthopedic surgery and surgical interventions on a patient with a high risk for thrombolysis).
Zwaan et al. evaluated the efficacy of three different kinds of temporary caval devices, including the Antheor filter, in 49 patients (2). None of the patients treated had clinically significant pulmonary embolism. Caval filter implantation led to three major complications, those related to baseline therapy, to filter implantationrelated procedures, and to the filter implant itself. Complications from the filter were seen in two cases of clinically insignificant subclavian venous thrombus, one case of catheter-related infection, one case of insignificant filter displacement by mishandling, one case of torn basket filaments that could be extracted through the catheter and one case of air embolism, all of which were not lethal. Based on this evidence, the increasing use of temporary implants appears to be justified. In addition, there is little risk of complications from caval filters, such as filter migration or penetration.
The use of a temporary filter provided significant benefits for the patient, as shown by the trapped thrombi in the removed filter, and there was a marked decrease in thrombus size. We have found that placement of a temporary caval filter can be a safe and effective adjunct during thrombolysis of massive thrombi in the IVC, in selected cases.
Currently, temporary IVC filters are not widely used because of problems with trapped thrombus and in timing the removal of the filter. Mechanical extraction of thrombi trapped in the filter requires an exact evaluation of the remaining clot. Current data suggests that the filter can be safely removed when the thrombi are less than 1 cm3 in size. However, there are no radiological techniques to evaluate the size of the residual thrombus, forcing examiners to rely on their clinical judgment.
Concerning the timing of removal, temporary vena cava filters are designed to remain implanted for a maximum of two weeks because the filter becomes covered by intima making extraction difficult after that time.
Current indications for placement of a permanent vena cava filter are as follows : 1) failure of anticoagulation to prevent recurrent embolism, 2) patients with venous thrombosis or pulmonary embolism who have contraindications to anti-coagulation or are difficult to manage on anti-coagulation, 3) patients with chronic recurrent pulmonary embolism with associated pulmonary hypertension and cor pulmonale, 4) following an episode of massive pulmonary embolism, 5) patients with DVT on anticoagulants who develop a complication forcing the discontinuation of anticoagulation (3) (4) (5) .
In evaluating the use of a permanent filter in our patient, we considered the following problems.
First, we had to consider the patient's age. Most interventional radiology techniques are relatively new. However, permanent caval filters, especially the Greenfield type, have been available for approximately twenty-five years, serving as the gold standard.
In patients younger than forty years old, there are several long-term safety issues to consider when deciding to use a permanent filter. Second, filters are usually placed below the level of the renal veins. However, Greenfield et al. reported that suprarenal placement of the Greenfield filter is safe and effective. There has not been any obstruction observed during the 16-year follow-up period for thrombus extending to the level of the renal veins or within those veins or for pregnant patients or women of child-bearing age (6).
After our report on permanent filter implantation in 1997, Decousus et al. (7) reported that in 400 patients with DVT, permanent inferior vena cava filters plus anticoagulation did not reduce the two-year mortality rate compared to that by anticoagulation alone. Our results suggest that temporary filters may be effective when trying to aggressively dissolve the thrombus invasively. These results may have been more compelling if we had used the temporary filter earlier in the patient's clinical course. Since we inserted the temporary filter 13 days after admission, we may not have gotten the full benefit of using the temporary filter.
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